US$ 24.33
glp-1 cognitive benefits The of Therapy: Beyond Weight Loss Weight-Loss Drugs May Reduce Buildup
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 147.Nahra, R

They also decrease systemic inflammation, a common issue in metabolic diseases

The SmPC advises that the risk of hypoglycaemia may be increased when Wegovy is used with these medications, and dose adjustments may be needed

Additionally, GLP-1 agonism directly influences insulin secretion and response

Finally, achieving lower HbA1c levels with molecules that do not induce hypoglycemia may be associated with a reduced need for intensification and a lower risk of therapeutic inertia